Akebia Therapeutics (AKBA) Non-Current Debt: 2019-2025
Historic Non-Current Debt for Akebia Therapeutics (AKBA) over the last 5 years, with Sep 2025 value amounting to $47.6 million.
- Akebia Therapeutics' Non-Current Debt rose 24.21% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 24.21%. This contributed to the annual value of $38.7 million for FY2024, which is 125.18% up from last year.
- Akebia Therapeutics' Non-Current Debt amounted to $47.6 million in Q3 2025, which was up 1.23% from $47.1 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Non-Current Debt registered a high of $97.2 million during Q3 2021, and its lowest value of $17.2 million during Q4 2023.
- Over the past 3 years, Akebia Therapeutics' median Non-Current Debt value was $38.0 million (recorded in 2024), while the average stood at $34.8 million.
- In the last 5 years, Akebia Therapeutics' Non-Current Debt plummeted by 49.58% in 2023 and then surged by 125.18% in 2024.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Non-Current Debt stood at $97.2 million in 2021, then reached $34.1 million in 2022, then plummeted by 49.58% to $17.2 million in 2023, then spiked by 125.18% to $38.7 million in 2024, then climbed by 24.21% to $47.6 million in 2025.
- Its Non-Current Debt stands at $47.6 million for Q3 2025, versus $47.1 million for Q2 2025 and $46.5 million for Q1 2025.